BNTC - Benitec Biopharma Ltd ADR logo

Benitec Biopharma Ltd ADR

BNTC

Benitec Biopharma develops genetic medicines using its Silence and Replace platform, which combines RNA interference with gene therapy. The company is advancing BB-301, an AAV-based treatment aimed at oculopharyngeal muscular dystrophy-related dysphagia.

โš•๏ธ Healthcare NASDAQ Listed 2015 $ AUD
$1,000 invested 10 years ago โ†’$25today

Score Overview

1 Year
Scoreโ€”
Net Growth-22.12%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score2.8
Net Growth-233.55%
Net TrendNever
Net Income Consistencyโ€”
Rev Growth9x
Rev Trend80%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-150.24%
Net Trend20%
Net Income Consistency
Rev Growth60.46%
Rev Trend70%
Revenue Consistency
All Time
Score
Net Growth-150.24%
Net Trend20%
Net Income Consistency
Rev Growth60.46%
Rev Trend70%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Benitec Biopharma Ltd ADR has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. BNTC does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 8.82โ€”
1 Year2025-10-22
$ 15.83-44.28%
5 Years2021-10-22
$ 60.18-85.34%
10 Years2016-10-21
$ 359.14-97.54%
All Time2015-08-18
$ 2.03K-99.57%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in AUD

Year
TTM$ 556K-$ 46M$ 188M
2025$ 0.00-$ 37M$ 97M
2024$ 216K-$ 21M$ 50M
2023$ 75K-$ 19M$ 2M
2022$ 73K-$ 18M$ 4M
2021$ 59K-$ 13M$ 19M
2020$ 97K-$ 8M$ 9M
2019$ 11M$ 2M$ 15M
2018$ 455.45K-$ 8M$ 11M
2017$ 450.31K-$ 4M$ 13M
2016$ 346.51K-$ 18M$ 13M
BNTC - Benitec Biopharma Ltd ADR logo

Benitec Biopharma Ltd ADR fundamental performance

Between 2020 and 2025, revenue declined from $ 97K to $ 0.00 and net income went from -$ 8M to -$ 37M. Revenue increased in 4 of those 5 years; net income in 0.

Across Benitec Biopharma Ltd ADR's full reported history, from 2016 to 2025, revenue declined from $ 346.51K to $ 0.00 and net income went from -$ 18M to -$ 37M. Revenue increased in 70% of the years measured; net income in 20%.

Benitec Biopharma Ltd ADR currently holds a 5-year HDB Score of 2.8 out of 10. How the HDB Score is calculated.

Membership

Explore BNTC with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies